Exploring Potential Bioactive Components of Persea americana for the Treatment of Rheumatoid Arthritis through Network Pharmacology

被引:1
|
作者
Swaroop, Akey Krishna [1 ]
Esakkimuthukumar, M. [1 ]
Saranya, R. [1 ]
Chandru, M. [1 ]
Sowbarnika, S. [1 ]
Sudharsan, J. [1 ]
Dhanush, V [1 ]
Prabha, Thangavelu [2 ]
Jubie, S. [1 ]
机构
[1] JSS Acad Higher Educ & Res, JSS Coll Pharm, Dept Pharmaceut Chem, Ooty, Tamil Nadu, India
[2] Affliated Tamil Nadu Dr MGR Med Univ, Nandha Coll Pharm, Dept Pharmaceut Chem, Erode 638052, Tamil Nadu, India
关键词
Persea americana; Rheumatoid arthritis; protein-protein interaction; protein-drug interactions; molecular docking; network pharmacology; MOLECULAR DOCKING; OPEN BABEL; MECHANISM; BINDING; DATABASE; OIL;
D O I
10.2174/0115733971294872240801113559
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Rheumatoid arthritis (RA) is a chronic autoimmune disease character-ized by inflammation and joint destruction, leading to significant disability and reduced quality of life. Current treatment options for RA have limitations, highlighting the need for novel therapeu-tic approaches. In this study, we employed network pharmacology methods to identify potential bioactive compounds from Persea Americana (avocado) for the treatment of RA. Materials and methods: We collected information on the phytoconstituents of avocados from the IMPPAT database and used Data Warrior software to filter out 64 plant constituents based on ADMET criteria. Target genes associated with avocado compounds were identified using the Bindingdb web server, resulting in 209 genes from Persea Americana. Protein-protein interaction (PPI) network analysis was performed using Cytoscape software to identify key genes and pro-teins involved in RA. Protein-drug interactions were analyzed, and ten avocado constituents with high binding affinity were identified. Results and discussion: Our network pharmacology analysis revealed that avocado constituents, particularly Luteolin, have the potential to be developed as novel therapeutics for RA. The PPI network analysis identified key genes and proteins associated with RA, providing insights into the molecular mechanisms of the disease. The high binding affinity observed between Luteolin and PTGS2, a protein involved in joint inflammation, suggests its potential effectiveness in mitigating RA-related inflammation. Conclusion: Our study highlights the potential of avocado constituents, particularly Luteolin, as promising therapeutics for the treatment of rheumatoid arthritis (RA). Through network pharma-cology analysis, we identified key target genes and proteins associated with RA, shedding light on the underlying molecular mechanisms of the disease.
引用
收藏
页数:24
相关论文
共 50 条
  • [21] Exploring the mechanism of Celastrol in the treatment of rheumatoid arthritis based on systems pharmacology and multi-omics
    Liuting Zeng
    Ganpeng Yu
    Kailin Yang
    Qi He
    Wensa Hao
    Wang Xiang
    Zhiyong Long
    Hua Chen
    Xiaojun Tang
    Lingyun Sun
    Scientific Reports, 14
  • [22] Use of Network Pharmacology to Investigate the Mechanism of the Compound Xuanju Capsule in the Treatment of Rheumatoid Arthritis
    Wei, Wenyang
    Lu, Wanpeng
    Chen, Xiaolong
    Yang, Yunfeng
    Zheng, Mengkai
    BIOMED RESEARCH INTERNATIONAL, 2021, 2021
  • [23] Exploring the mechanism of Celastrol in the treatment of rheumatoid arthritis based on systems pharmacology and multi-omics
    Zeng, Liuting
    Yu, Ganpeng
    Yang, Kailin
    He, Qi
    Hao, Wensa
    Xiang, Wang
    Long, Zhiyong
    Chen, Hua
    Tang, Xiaojun
    Sun, Lingyun
    SCIENTIFIC REPORTS, 2024, 14 (01)
  • [24] Network pharmacology analysis and clinical verification of Jishe Qushi capsules in rheumatoid arthritis treatment
    Li, Yujie
    Zhang, Nannan
    Peng, Xin
    Ma, Wukai
    Qin, Yuanxing
    Yao, Xueming
    Huang, Cong
    Zhang, Xudong
    MEDICINE, 2023, 102 (34) : E34883
  • [25] TO EXPLORE THE MECHANISM OF POLYGONATUM IN THE TREATMENT OF RHEUMATOID ARTHRITIS BASED ON NETWORK PHARMACOLOGY AND MOLECULAR DOCKING
    Chen, Ying
    Tian, Hao
    Ma, Qin
    Yang, Lunzhi
    Zhou, Xue
    Xiao, Ting
    Tao, Ling
    Wu, Linjing
    MEDICINE, 2023, 102 (30) : 85 - 85
  • [26] Exploring the bioactive properties and mechanism of Aegle marmelos in the treatment of inflammatory bowel disease through network pharmacology and a molecular docking approach
    Shah, Bhagyabhumi
    Solanki, Nilay
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2025, 17 (02):
  • [27] Revealing the Synergistic Mechanism of Multiple Components in Compound Fengshiding Capsule for Rheumatoid Arthritis Therapeutics by Network Pharmacology
    Duan, Hong
    Zhai, Ke-feng
    Khan, Ghulam J.
    Zhou, Jie
    Cao, Ting-yan
    Wu, Yu-qi
    Zhou, Ya-ru
    Cao, Wen-gen
    Gao, Gui-zhen
    Shan, Ling-ling
    CURRENT MOLECULAR MEDICINE, 2019, 19 (04) : 303 - 314
  • [28] Integrated serum pharmacochemistry, network pharmacology and pharmacokinetics to explore bioactive components of Gushudan in the treatment of osteoporosis
    Ren, Li
    Li, Qiuyu
    Zhang, Liwei
    Wang, Ruoyao
    Qin, Feng
    Zhao, Longshan
    Wei, Xiuyan
    Xiong, Zhili
    JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2023, 1225
  • [29] Network Pharmacology and Molecular Docking Based Repurposing of ACE Inhibitors as a Potential Candidate for Rheumatoid Arthritis
    Qasim, Sumera
    Khan, Yusra Habib
    Uttra, Ambreen Malik
    Tanveer, Nida
    Alanazi, Abdullah Salah
    Alzarea, Abdulaziz Ibrahim
    Alatawi, Ahmed D.
    Alotaibi, Nasser Hadal
    Mallhi, Tauqeer Hussain
    LATIN AMERICAN JOURNAL OF PHARMACY, 2024, 43 (02): : 433 - 445
  • [30] Metabolomics Combined with Network Pharmacology to Explore the Active Components and Mechanism of Tetrastigma planicaule (Hook.) Gagnep. in the Treatment of Rheumatoid Arthritis
    Qiu, Qin
    Qin, Chunping
    Li, Pengfei
    Meng, Xueyan
    Mo, Huiqing
    Huang, Chunying
    Wei, Jiangcun
    Zhen, Hanshen
    He, Yun
    Ouyang, Di
    Huang, Xiaodong
    JOURNAL OF CHEMISTRY, 2024, 2024